How Biomarkers Like NT-proβNP-1 Help Define Progression in ATTR-CM
By CardioNerds, Kevin M. Alexander, MD - Last Updated: June 13, 2024Drs. Anna Radakrishnan and Georgia Vasilakis Tsatiris, of The CardioNerds, continue their discussion with Dr. Kevin M. Alexander, shifting the topic to focus on how biomarkers, including NT-proβNP-1, can be used to assess disease progression in transthyretin amyloid cardiomyopathy. Dr. Alexander, who recently presented at the 2024 International Symposium on Amyloidosis, also analyzed the link between transthyretin increase and a lower risk of cardiovascular hospitalizations and death.
Advertisement
Advertisement
Related Posts
The REPAIR study offers the most comprehensive real-world assessment of outcomes after mitral TEER.
The ROLLER COASTR-EPIC22 trial is the first randomized head-to-head comparison of three plaque modification techniques.
Dr. Kevin Alexander speaks with The CardioNerds about the importance of providing swift treatment to patients with ATTR-CM.
The CardioNerds, Dr. Alexander discuss how acoramidis therapy works, and details data Dr. Alexander presented at AHA 2024.
Dr. Georgia Vasilakis Tsatiris of The CardioNerds speaks to Dr. Kevin Alexander about the impact of ATTR-CM.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.